Argentum Pharmaceuticals and Eli Lilly Settle Patent Dispute Over CIALIS®

NEW YORK, Aug. 22, 2017 /PRNewswire/ -- Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement and license agreement with Eli Lilly and Company related to Argentum's generic version of CIALIS® (tadalifil).

The agreement generally provides that Argentum may commence marketing its generic product no earlier than September 27, 2018. The specific date on which Argentum may launch its generic product and other details concerning the settlement have not been disclosed.

CIALIS® is a registered trademark of Eli Lilly and Company.